• Manjunatha KS Department of Pharmaceutical Chemistry, Kuvempu University, Post Graduate Centre, Kadur - 577 548, Chikkamagalur, Karnataka,India.
  • Manu Cp Department of Pharmaceutical Chemistry, Kuvempu University, Post Graduate Centre, Kadur - 577 548, Chikkamagalur, Karnataka, India.
  • Satyanarayan Nd Department of Pharmaceutical Chemistry, Kuvempu University, Post Graduate Centre, Kadur - 577 548, Chikkamagalur, Karnataka, India.
  • Vinay Kn Department of Chemistry, Tumkur University, Tumkur - 572 101, Karnataka, India
  • Vineetha Ms Department of Biochemistry, Centre for Post Graduate Studies, Jain University, Bengaluru, Karnataka, India.
  • Sunil More S School of Basic and Applied Sciences, Dayananda Sagar University, K.S. Layout, SM Hills, Bengaluru - 560 078, Karnataka, India


Objective: The objective of the study is acetylcholinesterase (AChE) inhibitory effect of 3-(1H-indol-3-yl)-1, 3-diphenylpropan-1-one derivatives by Ellman's method, physostigmine is used as positive control.

Method: 3-(1H-indol-3-yl)-1, 3-diphenylpropan-1-one derivatives were synthesized by the addition of chalcone (0.25 g, 1 mmol), indole (0.12 g, 1 mmol) in ethanol (5 ml), and concentrated hydrochloric acid (5 mmol %). These earlier synthesized compounds were screened for AChE inhibitors by modifying Ellman's method.

Results: Among the tested compounds, 3a and 3j were found to be having more potential than other compounds with half maximal inhibitory concentration values of 13.64 and 14.3 μg/ml, respectively. Whereas, compounds 3c, 3e, 3g, and 3i exhibited an average AChE inhibition of 16.4, 17.9, 17.6, and 21.1 μg/ml, respectively.

Conclusion: The compounds 3-(1H-indol-3-yl)-1, 3-diphenylpropan-1-one derivatives were found to be possible lead molecules in AChE inhibition and even though, the molecules were structurally dissimilar to that of the standard, still they exhibited a considerable degree of inhibition and encourage the researchers to look into the mode of action of their inhibition ability against AChE.

Keywords: Nil, Neurotransmitter, Dementia, Bovine serum albumin, Nil, Physostigmine.


1. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217(4558):408-14.
2. Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem 2000;7(3):303-39.
3. Yu L, Cao R, Yi W, Yan Q, Chen Z, Ma L, et al. Synthesis of 4-[(diethylamino)methyl]-phenol derivatives as novel cholinesterase inhibitors with selectivity towards butyrylcholinesterase. Bioorg Med Chem Lett 2010;20(11):3254-8.
4. Fernández-Bachiller MI, Pérez C, Campillo NE, Páez JA, González-Muñoz GC, Usán P, et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer’s disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem 2009;4(5):828-41.
5. Giacobini E. Therapy for Alzheimer disease. Symptomatic or neuroprotective. Mol Neurobiol 1994;9:115-8.
6. Zec RF, Burkett NR. Non-pharmacological and pharmacological treatment of the cognitive and behavioral symptoms of Alzheimer disease. NeuroRehabilitation 2008;23(5):425-38.
7. Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease. Ann Pharmacother 1999;33(4):441-50.
8. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 1997;278(16):1363-71.
9. Upadhyaya P, Seth V, Ahmad M. Therapy of Alzheimer’s disease: An update. Afr J Pharm Pharmacol 2010;4(6):408-21.
10. Rizzo S, Rivière C, Piazzi L, Bisi A, Gobbi S, Bartolini M. Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, β amyloid aggregation, and β neurotoxicity. J Med Chem 2008;51:2883-6.
11. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994;271(13):992-8.
12. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M. Multi-target-directed ligands to combat neuro degenerative diseases. J Med Chem 2008;51:347-72.
13. Kaufman PB, Duke JA, Brielmann H, Boik J, Hoyt JE. A comparative survey of leguminous plants as sources of the isoflavones, genistein and daidzein: Implications for human nutrition and health. J Altern Complement Med 1997;3:7-12.
14. Record IR, Dreosti IE, McInerney JK. The antioxidant activity of genistein in vitro. J Nutr Biochem 1995;6:481-5.
15. Ravindranath MH, Muthugounder S, Presser N, Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 2004;546:121-65.
16. Zhang LN, Cao P, Tan SH, Gu W, Shi L, Zhu HL. Synthesis and antimicrobial activities of 7-O-modified genistein derivatives. Eur J Med Chem 2008;43(7):1543-51.
17. Bang OY, Hong HS, Kim DH, Kim H, Boo JH, Huh K, et al. Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. Neurobiol Dis 2004;16(1):21-8.
18. Bagheri M, Joghataei MT, Mohseni S, Roghani M. Genistein ameliorates learning and memory deficits in amyloid ß(1-40) rat model of Alzheimer’s disease. Neurobiol Learn Mem 2011;95(3):270-6.
19. Manjunatha KS, Satyanarayan ND, Harishkumar S. Antimicrobial and in silico ADMET screening of novel (e)-n-(2-(1H-indol-3-yl-amino) vinyl)-3-(1-methyl-1H-indol-3-yl)-3-phenylpropanamide derivatives. Int J Pharm Pharm Sci 2016;8(10):251-6.
20. Jagadeesh NM, Mahadevan KM, Kumara MN, Prashantha N. Synthesis and molecular docking study of N-alkyl/aryl-2-aryl indol-3-yl glyoxylamides as novel anticancer agents. Int J Pharm Pharm Sci 2014;6:921-6.
21. Manjunatha KS, Manjulatha K, Satyanarayan ND, Kaviraj MY, Adarsha HJ. Anti-proliferative and ADMET screening of novel 3-(1H-indol-3-yl)-1, 3-diphenylpropan-1-one derivatives. Cogent Chem 2016;2:1172542.
22. Ismail MM, Kamel MM, Mohamed LW, Faggal SI. Synthesis of new indole derivatives structurally related to donepezil and their biological evaluation as acetylcholinesterase inhibitors. Molecules 2012;17(5):4811-23.
23. Zhang X, Wang J, Hong C, Luo W, Wang C. Design, synthesis and evaluation of genistein-polyamine conjugates as multi-functional anti-Alzheimer agents. Acta Pharm Sin B 2015;5(1):67-73.
24. Mohammadi-Farani A, Ahmadi A, Nadri H, Aliabadi A. Synthesis, docking and acetylcholinesterase inhibitory assessment of 2-(2-(4-Benzylpiperazin-1-yl) ethyl) isoindoline-1, 3-dione derivatives with potential anti-Alzheimer effects. Daru J Pharm Sci 2013;21:47-55.
25. Braak H, Braak E. Pathology of Alzheimer’s disease. In: Calne D, editor. Neuro Degenrative Diseases. Philadelphia, PA: Saunders; 1994. p. 585-614.
26. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002;297(5580):353-6.
27. Suh YH. An etiological role of amyloidogenic carboxyl-terminal fragments of the beta-amyloid precursor protein in Alzheimer’s disease. J Neurochem 1997;68(5):1781-91.
28. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004;84(2):361-84.
29. Brion JP. Neurofibrillary tangles and Alzheimer’s disease. Eur Neurol 1998;40(3):130-40.
30. Hernández F, Avila J. Tauopathies. Cell Mol Life Sci 2007;64(17):2219-33. 31. Chun W, Johnson GV. The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci 2007;12:733-56.
32. Pappas BA, Bayley PJ, Bui BK, Hansen LA, Thal LJ. Choline acetyltransferase activity and cognitive domain scores of Alzheimer’s patients. Neurobiol Aging 2000;21(1):11-7.
33. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996;46(1):130-5.
396 Views | 506 Downloads
How to Cite
KS, M., M. Cp, S. Nd, V. Kn, V. Ms, and S. More S. “ACETYLCHOLINESTERASE INHIBITORY EFFECT OF 3-(1H-INDOL-3-YL)-1, 3-DIPHENYLPROPAN-1-ONE DERIVATIVES”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 8, Aug. 2017, pp. 83-86, doi:10.22159/ajpcr.2017.v10i8.18730.
Original Article(s)